120 related articles for article (PubMed ID: 38010733)
1. Disruption of the TP53 locus in osteosarcoma leads to TP53 promoter gene fusions and restoration of parts of the TP53 signalling pathway.
Saba KH; Difilippo V; Kovac M; Cornmark L; Magnusson L; Nilsson J; van den Bos H; Spierings DC; Bidgoli M; Jonson T; Sumathi VP; Brosjö O; Staaf J; Foijer F; Styring E; Nathrath M; Baumhoer D; Nord KH
J Pathol; 2024 Feb; 262(2):147-160. PubMed ID: 38010733
[TBL] [Abstract][Full Text] [Related]
2. Patterns of structural variants within TP53 introns and relocation of the TP53 promoter: a commentary
Beird HC; Lin D; Lazar AJ; Futreal PA
J Pathol; 2024 Jun; 263(2):131-134. PubMed ID: 38482738
[TBL] [Abstract][Full Text] [Related]
3. TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome.
Ribi S; Baumhoer D; Lee K; Edison ; Teo AS; Madan B; Zhang K; Kohlmann WK; Yao F; Lee WH; Hoi Q; Cai S; Woo XY; Tan P; Jundt G; Smida J; Nathrath M; Sung WK; Schiffman JD; Virshup DM; Hillmer AM
Oncotarget; 2015 Apr; 6(10):7727-40. PubMed ID: 25762628
[TBL] [Abstract][Full Text] [Related]
4. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
[TBL] [Abstract][Full Text] [Related]
5. TP53 Mutations and Survival in Osteosarcoma Patients: A Meta-Analysis of Published Data.
Chen Z; Guo J; Zhang K; Guo Y
Dis Markers; 2016; 2016():4639575. PubMed ID: 27239089
[TBL] [Abstract][Full Text] [Related]
6. Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutations.
Alidousty C; Baar T; Martelotto LG; Heydt C; Wagener S; Fassunke J; Duerbaum N; Scheel AH; Frank S; Holz B; Binot E; Kron A; Merkelbach-Bruse S; Ihle MA; Wolf J; Buettner R; Schultheis AM
J Pathol; 2018 Sep; 246(1):67-76. PubMed ID: 29885057
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells.
Di Fiore R; Marcatti M; Drago-Ferrante R; D'Anneo A; Giuliano M; Carlisi D; De Blasio A; Querques F; Pastore L; Tesoriere G; Vento R
Bone; 2014 Mar; 60():198-212. PubMed ID: 24373920
[TBL] [Abstract][Full Text] [Related]
8. p53 gene mutations in osteosarcomas of low-grade malignancy.
Radig K; Schneider-Stock R; Haeckel C; Neumann W; Roessner A
Hum Pathol; 1998 Nov; 29(11):1310-6. PubMed ID: 9824113
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma.
Negri GL; Grande BM; Delaidelli A; El-Naggar A; Cochrane D; Lau CC; Triche TJ; Moore RA; Jones SJ; Montpetit A; Marra MA; Malkin D; Morin RD; Sorensen PH
J Pathol; 2019 Nov; 249(3):319-331. PubMed ID: 31236944
[TBL] [Abstract][Full Text] [Related]
10. [Molecular analysis of tumor suppressor genes p16INK4 and TP53 of osteosarcomas in Spanish children].
Patiño García A; Sierrasesúmaga Ariznabarreta L
An Esp Pediatr; 1997 Nov; 47(5):478-82. PubMed ID: 9586287
[TBL] [Abstract][Full Text] [Related]
11. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
12. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
13. Osteosarcomas With Few Chromosomal Alterations or Adult Onset Are Genetically Heterogeneous.
Difilippo V; Saba KH; Styring E; Magnusson L; Nilsson J; Nathrath M; Baumhoer D; Nord KH
Lab Invest; 2024 Jan; 104(1):100283. PubMed ID: 37931683
[TBL] [Abstract][Full Text] [Related]
14. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
15. Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.
Lorenz S; Barøy T; Sun J; Nome T; Vodák D; Bryne JC; Håkelien AM; Fernandez-Cuesta L; Möhlendick B; Rieder H; Szuhai K; Zaikova O; Ahlquist TC; Thomassen GO; Skotheim RI; Lothe RA; Tarpey PS; Campbell P; Flanagan A; Myklebost O; Meza-Zepeda LA
Oncotarget; 2016 Feb; 7(5):5273-88. PubMed ID: 26672768
[TBL] [Abstract][Full Text] [Related]
16. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
17. [The clonal evolution of osteosarcomas].
Baumhoer D
Pathologe; 2016 Nov; 37(Suppl 2):163-168. PubMed ID: 27651058
[TBL] [Abstract][Full Text] [Related]
18. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression.
Novello C; Pazzaglia L; Conti A; Quattrini I; Pollino S; Perego P; Picci P; Benassi MS
PLoS One; 2014; 9(12):e114757. PubMed ID: 25490093
[TBL] [Abstract][Full Text] [Related]
19. The early evolutionary landscape of osteosarcoma provides clues for targeted treatment strategies.
Kovac M; Ameline B; Ribi S; Kovacova M; Cross W; Barenboim M; Witt O; Bielack S; Krieg A; Hartmann W; Nathrath M; Baumhoer D
J Pathol; 2021 Aug; 254(5):556-566. PubMed ID: 33963544
[TBL] [Abstract][Full Text] [Related]
20. Fischer-344 Tp53-knockout rats exhibit a high rate of bone and brain neoplasia with frequent metastasis.
Hansen SA; Hart ML; Busi S; Parker T; Goerndt A; Jones K; Amos-Landgraf JM; Bryda EC
Dis Model Mech; 2016 Oct; 9(10):1139-1146. PubMed ID: 27528400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
